Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog

Carcinogenesis

Volumn 19, Issue 1, 1998, Pages 213-217

  Johnson, A Sherwood ^a   Couto, C Guillermo ^a   Weghorst, Christopher M ^b  

^a Department of Veterinary Biosciences   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CODON; CONTROLLED STUDY; DOG; EXON; GENE MUTATION; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; BONE NEOPLASMS; CODON; CONSERVED SEQUENCE; DNA PRIMERS; DOG DISEASES; DOGS; GENES, P53; HUMANS; OSTEOSARCOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0031869268     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/19.1.213     Document Type: Article

References (60)

1. Greenblatt, M.S., Bennett, W.P., Hollstein, M. and Harris, C.C. (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
2. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. (1991) p53 mutations in human cancers. Science, 253, 49-53.
3. Hahn, K.A., Bravo, L., Adams, W.H. and Frazier, D.L. (1994) Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo, 8, 133-144.
4. Lane, D.P. (1993) A death in the life of p53. Nature, 362, 786-787.
5. Levine, A., Momand, J. and Finlay, C. (1991) The p53 tumour suppressor gene. Nature, 351, 453-456.
6. Callahan, R. (1992) p53 mutations, another breast cancer prognostic factor. J. Natl Cancer Inst., 84, 826-827.
7. Harris, C.C. and Hollstein, M. (1993) Clinical implications of the p53 tumor suppressor gene. N. Engl J. Med., 329, 1318-1327.
8. Lowe, S.W., Ruley, H.E., Jacks, T. and Housman, D.E. (1993) p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
9. Andreassen, A., Oyjord, T., Hovig, E. et al. (1993) p53 abnormalities in different subtypes of human sarcomas. Cancer Res., 53, 468-471.
10. Hoogerwerf, W.A., Hawkins, A.L., Perlman, E.J. and Griffin, C.A. (1994) Chromosome analysis of nine osteosarcomas. Genes Chrom. Cancer, 9, 88-92.
11. Miller, C.W., Aslo, A., Tsay, C., Slamon, D., Ishizaki, K., Toguchida, J., Yamamuro, T., Lampin, B. and Koeffler, H.P. (1990) Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res., 50, 7950-7954.
12. Toguchida, J., Ishizaki, K., Sasaki, M., Ikenaga, M., Sugimoto, M., Kotoura, Y. and Yamamuro, T. (1988) Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res., 48, 3939-3943.
13. Toguchida, J., Yamaguchi, T., Ritchie, B. et al. (1992) Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res., 52, 6194-6199.
14. Iavarone, A., Matthay, K.K., Steinkirchner, T.M. and Israel, M.A. (1992) Germ-line and somatic p53 mutations in multifocal osteogenic sarcoma. Proc. Natl Acad. Sci. USA, 89, 4207-4209.
15. Miller, C.W., Aslo, A., Won, A., Tan, M., Lampkin, B. and Koeffler, H.P. (1996) Alterations of the p53, Rb, and MDM2 genes in osteosarcoma. J. Cancer Res. Clin. Oncol., 122, 559-565.
16. Scholz, R.B., Kabisch, H., Weber, B., Roser, K., Delling, G. and Winkler, K. (1992) Studies of the RB1 gene and the p53 gene in human osteosarcomas. Ped. Hem. Oncol., 9, 125-137.
17. Smith-Sorensen, B., Gebhardt, M.C., Kloen, P., McIntyre, J., Aguilar, F., Cerutti, P. and Borresen, A.L. (1993) Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Human Mut., 2, 274-285.
18. Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. and Cline, M.J. (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl Acad. Sci. USA, 84, 7716-7719.
19. Grundmann, E., Ueda, Y., Schneider-Stock, R. and Roessner, A. (1995) New aspects of cell biology in osteosarcoma. Path. Res. Pract., 191, 563-570.
20. Park, H. and Park, Y. (1995) Expression of p53 protein, PCNA, and Li-67 in osteosarcomas of bone. J. Kor. Med. Sci., 10, 360-367.
21. Sagartz, J.E., Bodley, W.L., Gamblin, R.M., Couto, C.G., Tierney, L.A. and Capen, C.C. (1996) p53 tumor suppressor gene overexpression in osteogenic tumors of dogs. Vet. Path., 33, 213-221.
22. Ueda, Y., Dockhorn-Dworniczak, B., Blasius, S., Mellin, W., Wuisman, P., Bocker, W. and Roessner, A. (1993) Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J. Cancer Res. Clin. Oncol., 119, 172-178.
23. Wadayama, B., Toguchida, J., Yamaguchi, T., Sasaki, M.S., Kotoura, Y. and Yamamuro, T. (1993) p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br. J. Cancer, 68, 1134-1139.
24. Hartley, A.L., Birch, J.M., Marsden, H.B. and Harris, M. (1986) Breast cancer risk in mothers of children with osteosarcoma and chondrosarcoma. Br. J. Cancer, 54, 819-823.
25. Li, F.P., Fraumeni, J.F. Jr., Mulvihill, J.J., Blattner, W.A., Drefus, M.G., Tucker, M.A. and Miller, R.W. (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res., 48, 5358-5362.
26. Malkin, D., Frederick, P.L., Strong, L. et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233-1238.
27. McIntyre, J.F., Smith-Sorensen, B., Friend, S.H. et al. (1994) Germ line mutations of the p53 tumor suppressor gene in children with osteosarcoma. J. Clin. Oncol., 12, 925-930.
28. Porter, D.E., Holden, S.T., Steel, C.M., Cohen, B.B., Wallace, M.R. and Reid, R. (1992) A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni families. J. Bone Joint Surg., 74B, 883-886.
29. Lavigueur, A., Maltby, V., Mock, D., Rossant, J. Pawson, L. and Bernstein, A. (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol., 9, 3982-3991.
30. Wilkie, T.M., Schmidt, R.A., Baetscher, M. and Messing, A. (1994) Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen. Oncogene, 9, 2889-2895.
31. Radinsky, R., Fidler, I.J., Price, J.E., Esumi, N., Tsan, R., Petty, C.M., Bucana, C.D. and Bar-Eli, M. (1994) Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene, 9, 1877-1883.
32. Wang, J., Bucana, C.D., Roth, J.A. and Zhang, W.W. (1995) Apoptosis induced in human osteosarcoma cell is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Therapy, 2, 9-17.
33. Miyakoshi, J., Nobuyuki, Y., Shuji, O. and Takebe, H. (1995) Changes in radiation sensitivity of human osteosarcoma cells after p53 introduction. Japan. J. Cancer Res., 86, 711-713.
34. Hewitt, H.B. (1978) The choice of animal tumors for experimental studies of cancer therapy. Adv. Cancer Res., 27, 149-200.
35. Brodey, R.S. (1979) The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. Yale J. Biol. Med., 52, 345-361.
36. MacEwen, E.G. (1990) Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Met. Rev., 9, 125-136.
37. Misdorp, W. (1980) Animal model: canine osteosarcoma. Am. J. Path., 98, 285-288.
38. Liu, S.K., Dorfman, H.D., Hurvitz, A.I. and Patnaik, A.K. (1977) Primary and secondary bone tumors in the dog. J. Small Anim. Pract., 18, 313-326.
39. Malawar, M.M., Link, M.P. and Donaldson, S.S. (1993) Sarcomas of bone. In DeVita, V.T., Hellman, S. and Rosenberg, S.A. (eds) Cancer: Principles and Practice of Oncology. J.B. Lippencott, Co., Philadelphia, 4th edn, pp. 1509-1566.
40. Brodey, R.S. and Riser, W.H. (1969) Canine osteosarcoma. A clinicopathologic study of 194 cases. Clin. Orthop. Rel. Res., 62, 54-64.
41. Withrow, S.J., Powers, B.E., Straw, R.C. and Wilkins, R.M. (1991) Comparative aspects of osteosarcoma: dog versus man. Clin. Ortho. Relat. Res., 270, 159-168.
42. Gillette, E.L. (1980) Spontaneous canine neoplasms as models for therapeutic agents. In Fidler, I.J. and White, R.J. (eds) Design of Models for Testing Cancer Therapeutic Agents. Van Nostrand Reinhold, New York, pp. 185-192.
43. Goldschmidt, M.H. and Thrall, D.E. (1985) Malignant bone tumors in the dog. In Newton, C.D. and Nunamaker, D.M. (eds) Textbook of Small Animal Orthopaedics. J.B. Lippincott, Philadelphia, PA, pp. 887-898.
44. Weghorst, C.M., Buzard, G.S., Calvert, R.J., Hulla, J.E. and Rice, J.M. (1995) Cloning and sequence of a processed p53 pseudogene from rat: a potential source of false 'mutations' in PCR fragments of tumor DNA. Gene, 166, 317-322.
45. Zakut-Houri, R., Oren, M., Bienz, B., Lavie, V., Hazum, S. and Givol, D. (1983) A single gene and a pseudogene for the cellular tumour antigen p53. Nature, 306, 594-597.
46. Kraegel, S.A., Gumerlock, P.H., Dungworth, D.L., Oreffo, V.I.C. and Madewell, B.R. (1992) K-ras activation in non-small cell lung cancer in the dog. Cancer Res., 52, 4724-4727.
47. Devilee, P., Van Leeuwen, I.S., Voesten, A., Rutteman, G.R., Jan H.V. and Cees J.C. (1994) The canine p53 gene is subject to somatic mutations in thyroid carcinoma. Anticancer Res., 14, 2039-2046.
48. Chou, Q., Russell, M., Birch, D.E., Raymond, J. and Bloch, W. (1992) Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications. Nucl. Acids Res., 20, 1717-1723.
49. Kellogg, D.E., Rybalkin, I., Chen, S., Mukhamedova, N., Vlasik, T., Siebert, P.D. and Chenchik, A. (1994) TaqStart Antibody: 'hot start' PCR facilitated by a neutralizing monoclonal antibody directed against Taq DNA polymerase. BioTechniques, 16, 1134-1137.
50. Hongyo, T., Buzard, G., Calvert, R. and Weghorst, C.M. (1993) 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism. Nucl. Acid Res., 21, 3637-3642.
51. Sarkar, G. and Sommer, S.S. (1990) The 'megaprimer' method of site-directed mutagenesis. BioTechniques, 8, 404-407.
52. Cariello, N.F., Douglas, G.R. and Soussi, T. (1996) Databases and software analysis of mutations in the human p53 gene, the human hprt gene and the lacZ gene in transgenic rodents. Nucl. Acids Res., 24, 119-120.
53. Hainuat, P., Soussi, T., Shomer, B., Hollenstein, M., Greenblatt, M., Hovig, E., Harris, C.C. and Montesano, R. (1996) Database of p53 somatic mutations in human tumors and cell lines. Nucl. Acids Res., 25, 151-157.
54. Cho, Y., Gorina, S., Jeffrey, P. and Pavletich, N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: a framework for understanding how mutations inactivate p53. Science, 265, 346-355.
55. Nakayama, T., Toguchida, J., Wadayama, B., Kanoe, H., Kotoura, Y. and Sasaki, M.S. (1995) MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Int. J. Cancer, 64, 342-346.
56. Benedict, W.F., Fung, Y.K.T. and Murphree, A.L. (1988) The gene responsible for the development of retinoblastoma and osteosarcoma. Cancer, 62, 1691-1694.
57. Townsend, T., Kochevar, D.T. and Straw, R.C. (1993) Tumor suppressor gene changes in canine osteosarcoma. Vet. Cancer News, 16, 8-9.
58. Weischelbaum, R.R., Beckett, M. and Diamond, A. (1988) Some retinoblastomas, osteosarcomas and soft tissue sarcomas may share a common etiology. Proc. Natl Acad. Sci. USA, 85, 2106-2109.
59. Engstrom, W., Barrios, C., Azavedo, E., Mollermark, G., Kangstrom, L.E., Aliason, I. and Larsson, O. (1987) Expression of c-myc in canine mammary tumors. Anticancer Res., 7, 1235-1238.
60. Kraegel, S.A., Pazzi, K.A. and Madewell, B.R. (1995) Sequence analysis of canine p53 in the region of exons 3-8. Cancer Lett., 92, 181-186.